The future of 161 Maiden Lane, often referred to as the "Leaning Tower of Lower Manhattan," has returned to the spotlight following recent discussions about stalled development projects in New York City.

A recent New York YIMBY article explores how the structural issues at the former Pfizer headquarters conversion have renewed attention on 161 Maiden Lane, a residential tower whose construction has remained unfinished for several years.

Construction at the project was halted after foundation issues caused the building to lean during development. While engineers have stated that the structure does not pose an immediate safety concern, the tower has remained incomplete as legal and financial matters continue to delay its future.

The project serves as an example of the complexities that can arise during large-scale developments, particularly in New York City's evolving real estate market. It also highlights the challenges developers, lenders, and municipalities face when projects encounter unexpected setbacks.

As Lower Manhattan continues to evolve, the future of 161 Maiden Lane remains an important project to watch. Whether the building is completed under new ownership or another solution emerges, its eventual outcome will be closely followed by the commercial real estate community.

At Tri State Commercial, we continue to monitor significant developments across New York City and New Jersey that shape the region's commercial real estate landscape.

Source: New York YIMBY, "Why the Collapse of the Pfizer Conversion Means It's Time to Address the Leaning Tower of Lower Manhattan at 161 Maiden Lane," published July 7, 2026.